megestrol acetate has been researched along with etoposide in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (50.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Baker, TR; Cornelison, TL; Driscoll, DL; Piver, MS | 1 |
| Ghosh, C; Jett, JR; Jung, SH; Kugler, JW; Kuross, SA; Loprinzi, CL; Mailliard, JA; Maksymiuk, AW; Owen, D; Rowland, KM; Schaefer, PL; Shaw, EG; Tschetter, LK; Washburn, JH; Webb, TA | 1 |
| Bruera, E; Hewitt, J; Palmer, M; Rapp, E; Thaell, JF; Urtasun, R; Wood, L | 1 |
| Fossella, FV; Glisson, BS; Khuri, FR; Lee, JS; Markowitz, AB; Murphy, WK; Shin, DM | 1 |
| Craffey, M; Dowlati, A; Levitan, N; MacKay, W; McKenney, J; Remick, SC; Tahsildar, H | 1 |
5 trial(s) available for megestrol acetate and etoposide
| Article | Year |
|---|---|
Cisplatin, adriamycin, etoposide, megestrol acetate versus melphalan, 5-fluorouracil, medroxyprogesterone acetate in the treatment of endometrial carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Endometrial Neoplasms; Etoposide; Female; Fluorouracil; Humans; Medroxyprogesterone Acetate; Megestrol; Megestrol Acetate; Melphalan; Middle Aged; Prospective Studies; Survival Rate | 1995 |
Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study.
Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cachexia; Carcinoma, Small Cell; Cisplatin; Double-Blind Method; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Megestrol; Megestrol Acetate; Pain Measurement; Quality of Life; Survival Analysis; Survival Rate; Thromboembolism | 1996 |
Results of a phase III, double-blind, placebo-controlled trial of megestrol acetate modulation of P-glycoprotein-mediated drug resistance in the first-line management of small-cell lung carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Disease-Free Survival; Double-Blind Method; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lung Neoplasms; Male; Megestrol Acetate; Middle Aged; Neoplasm Proteins; Vincristine | 1998 |
Phase II trial of recombinant IFN-alpha2a with etoposide/cisplatin induction and interferon/megestrol acetate maintenance in extensive small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Interferon alpha-2; Interferon-alpha; Lung Neoplasms; Male; Megestrol Acetate; Middle Aged; Recombinant Proteins | 1998 |
A brief intensive cisplatin-based outpatient chemotherapy regimen with filgrastim and megestrol acetate support for advanced non-small cell lung cancer: results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appetite Stimulants; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lung Neoplasms; Male; Megestrol Acetate; Mesna; Middle Aged; Protective Agents; Recombinant Proteins; Survival Analysis; Treatment Outcome | 1998 |
5 other study(ies) available for megestrol acetate and etoposide
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |